Literature DB >> 18042753

Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.

Robert I Misbin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18042753     DOI： 10.2337/dc07-1908

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  3 in total

1.  First do no harm. Improving drug safety through legislation and independent research.

Authors:  Mark Greener
Journal:  EMBO Rep       Date:  2008-03       Impact factor: 8.807

Review 2.  Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.

Authors:  Yoon Kong Loke; Chun Shing Kwok; Sonal Singh
Journal:  BMJ       Date:  2011-03-17

3.  Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records.

Authors:  John S Brownstein; Shawn N Murphy; Allison B Goldfine; Richard W Grant; Margarita Sordo; Vivian Gainer; Judith A Colecchi; Anil Dubey; David M Nathan; John P Glaser; Isaac S Kohane
Journal:  Diabetes Care       Date:  2009-12-15       Impact factor: 19.112
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.